Acarbose dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Acarbose is an old, cheap diabetes pill that slows how fast starch turns into sugar. In people, a large heart study found no heart benefit, and it has never been tested for ageing. In the US government's mouse program, it made male mice live 6 to 22 percent longer.
Evidence grade for Acarbose: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 2 human studies where nobody was given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
2 human studies where nobody was given it
4 effects reported, 2 unwanted, 2 wanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Acarbose is an old, cheap diabetes pill. It slows down how fast your gut turns starch into sugar. So your blood sugar spikes less after a meal. People in longevity circles take it because of results in mice.
What people take it for
- Living longer, because of the mouse results.
- Flattening blood sugar spikes after meals full of carbs.
- A cheap, old add-on to a longevity stack.
What studies in people showed
Start with people. In the big heart study, 6,522 people with heart disease took acarbose or a dummy pill for five years. Heart attacks, strokes and heart deaths came out the same in both groups. Fewer people on it went on to get diabetes. Nobody has tested it for ageing in people. The only tries were a pilot in 8 people and a study in 28 people that stopped for lack of money. Now mice. In the US government's ageing test program, male mice lived 6 to 22 percent longer. It still worked when started late in life. Females gained much less.
What people report
Reports, not study results
The good
- People wearing glucose monitors see a flatter blood sugar curve after meals.
- Users say starting low, and taking it only with the biggest carb meal, makes it easier to live with.
The bad
- Gas and bloating are reported by nearly everyone. They are worse with starchy meals.
- In the maker's own study data, gas hit 74 percent of people on it, diarrhoea 31 percent and belly pain 19 percent.
Where these come from: The gas, bloating and glucose monitor reports are from longevity forums and glucose monitor groups. They are not from a study. The side effect rates are from the label's study data on this page.
My bottom line
The mouse result is real, and it is in male mice. In people it has never been tested for ageing, and the gas is not a small side effect. Get your blood sugar tested first. If it is a problem, that is a talk with your doctor.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
What people using it report
Real people telling you what happened to them. Nobody checked it, and the people who post are not a fair sample, so it cannot prove anything works. It is still the best guide on this page to what people actually do with Acarbose, what they expect, and what goes wrong. The full account, including the negative reports, is below.
Nothing indexed yet
The 4 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Acarbose?
Acarbose is an old, cheap diabetes pill that slows how fast starch turns into sugar. In people, a large heart study found no heart benefit, and it has never been tested for ageing. In the US government's mouse program, it made male mice live 6 to 22 percent longer.
Acarbose blocks the gut enzymes that break starch down into sugar. So carbs travel further down the gut, and the blood sugar spike after a meal is flattened. It is an old, cheap diabetes drug, used for decades. In a heart study of 6,522 people, it did not cut heart attacks, strokes or heart deaths, though fewer people went on to get diabetes. The only tests for ageing in people are an 8-person pilot and a 28-person study that ended early for lack of money. In mice, the story is different. In the US government's ageing test program, across three separate groups of mice, four doses and two starting ages, the typical male lived 6 to 22 percent longer. It still worked when started at 16 months, which is late middle age for a mouse. The effect in females was much smaller, and higher doses did not do more.
How does Acarbose work?
It blocks gut enzymes called alpha-glucosidases, so complex carbs break down more slowly and blood sugar rises less after a meal. The undigested carbs reach the large bowel, where gut bacteria ferment them. That causes the usual side effects, and it may also add to the effect on blood sugar and body chemistry.
What have studies in people found about Acarbose?
Plenty for diabetes and blood sugar, close to none for ageing. Acarbose has been prescribed for decades, so its safety and side effects are well known. Nobody has run a study of it for ageing.
- ACE: 6,522 people with heart disease and blood sugar on the high side of normal, followed for 5 years. Heart attacks, strokes and heart deaths were no lower than on a dummy pill. It did cut the number who went on to get type 2 diabetes.
- STOP-NIDDM reported a heart benefit that made acarbose's name. Outside experts have challenged how it was run and reported. The review that backed it up was written by staff of the drug's maker, pooling that maker's own studies.
- Side effects are the real limit. In the label's own study data, gas hit 74 percent on acarbose against 29 percent on a dummy pill. Diarrhoea hit 31 percent against 12 percent, and belly pain 19 percent against 9 percent.
- Total testing for ageing in people: a pilot in 8 people, and a 28-person study that was stopped for lack of money. No study has tested acarbose for any ageing result in people.
What this does not tell you: The mouse result is strong, and it is a mouse result. Nothing has been measured about acarbose and human ageing. The one large outcome study in people found nothing on the main thing it measured.
What do people who took Acarbose report?
This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.
- Stomach effects are reported by nearly everyone, mainly gas and bloating. They get worse with higher doses and with starchy meals.
- Users often describe starting at a very low dose, raising it slowly over weeks, and taking it only with the biggest carb meal of the day.
- People wearing glucose monitors often report a flatter blood sugar curve after meals. That is the drug doing what it is known to do. It is not evidence of any effect on ageing.
Sources: Longevity forums and continuous glucose monitoring communities. Uncontrolled self-report, included for expectations and side effects rather than as evidence.
The state of the research
On the human side, the record is thin and mostly negative. The heart claim rests on a study whose conduct has been formally disputed. The much larger, later ACE study found nothing on its main measure. There is no patent to protect and no company with a reason to pay for an ageing study. That same money problem empties the study record across most of this site.
In mice, acarbose stands out. The US government's ageing test program was built to catch results that do not repeat. It runs the same test at three separate sites, and most of what it tests fails. Acarbose is one of the few that worked, worked again, and still worked when started late in life. That is unusual and worth attention.
But it is all in mice, and the gap between the sexes is big: males gained far more than females. Higher doses did not help more. Four times the dose gave no extra effect. That suggests the effect tops out early, which is useful to know, but it makes finding a human dose harder.
The evidence, in charts
Fig. 1a · how many people
6,522people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| Lancet Diabetes and Endocrinology 2017 | 6,522 | 100% |
The whole total is one study of 6,522. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 4 sources here are studies in people. The rest are not.
- Study in people · done in people250%
- Animal study · done in animals250%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 4 different years, 2003 to 2019, counted from the list of sources on this page. The newest source on file is from 2019, more than five years ago. Research on it may have gone quiet.
Fig. 3 · legal status at a glance
US
Approved
UK
Prescription
AU
Prescription
CA
Prescription
Approved in 1 of 4, by prescription in 3, not approved in 0. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 645.6 Da
- Half-life
- About 2 hoursShort, 1 to 6 hours
- Chain length
- None on file
Half-life as stated on file: About 2 hours; acts locally in the gut with minimal systemic absorption
No amino acid sequence is on file for Acarbose, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2017Effect of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Acarbose did not protect the heart once it was tested properly. 6,522 people with heart disease and blood sugar on the high side of normal took either acarbose or a dummy pill for five years. Heart attacks, strokes and heart deaths happened about as often in each group. A trial this large would have found a heart benefit if there was one to find. The drug did do one thing. Fewer people on it went on to develop full diabetes.
6,522 patients followed 5 years: no reduction in the primary cardiovascular composite (HR 0.98, p = 0.73), while confirming a reduction in progression to diabetes.
- Study in people2003Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial
The study that gave acarbose its heart reputation has been picked apart, and the larger study that followed did not back it up. Other researchers formally challenged it over how many people dropped out of each group, how it was run and how the results were written up. The later ACE study was several times the size and found no heart benefit at all. Treat the heart claim as unsupported.
The trial that generated acarbose's cardiovascular reputation. Its validity has been formally challenged over differential dropout, blinding and reporting, and the later and much larger ACE trial did not confirm it.
- Animal study2014Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males
In mice: in the first group tested by the US government's ageing program, acarbose made males live longer. The test ran at three separate sites using mixed-breed mice.
The first Interventions Testing Program cohort reporting acarbose extending male median lifespan, in genetically heterogeneous mice across three independent sites.
- Animal study2019Acarbose improves health and lifespan in aging HET3 mice
In mice: the result held up across doses and starting ages. Started late, at 16 months, it still kept much of the benefit in males.
Replication and extension across doses and starting ages, including a late start at 16 months that preserved much of the effect in males.
Common questions
Has Acarbose been tested in people?
Not in a completed trial cited here. 2 human studies where nobody was given it. Acarbose is an old, cheap diabetes pill that slows how fast starch turns into sugar. In people, a large heart study found no heart benefit, and it has never been tested for ageing. In the US government's mouse program, it made male mice live 6 to 22 percent longer.
What is the Acarbose dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 2 human studies where nobody was given it
Is Acarbose FDA-approved?
Approved for type 2 diabetes. The original US brand was discontinued and generic versions are sold. In Canada, the original brand was taken off the market in 2023, and a generic is available.
Why is acarbose interesting for longevity?
Because in mice it made males live longer in the US government's ageing test program. That program runs at three sites to weed out results that do not repeat, and most compounds tested in it fail. Acarbose worked even when started in late middle age.
Does it work in humans for ageing?
Nobody knows, because nobody has tested it. The whole record for ageing in people is a pilot in 8 people and a 28-person study stopped for lack of money. Its big studies in people were about diabetes and heart disease, and the largest found no heart benefit on its main measure.
Why did the effect differ so much between male and female mice?
Nobody knows why. It is common in this research, not unique to acarbose. Several compounds in the same program show big gaps between males and females, and the reasons are not known.
What are the side effects?
Almost all stomach and gut problems, because the drug works by sending undigested carbs to gut bacteria. In the maker's own study data, gas hit 74 percent of people taking it, against 29 percent on a dummy pill.